TCRT - Alaunos Therapeutics, Inc.
Previous close
1.74
0.040 2.299%
Share volume: 21,765
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$1.70
0.04
0.02%
Fundamental analysis
7%
Profitability
0%
Dept financing
23%
Liquidity
48%
Performance
0%
Performance
5 Days
2.35%
1 Month
6.10%
3 Months
-16.35%
6 Months
155.88%
1 Year
-11.11%
2 Year
114.34%
Key data
Stock price
$1.74
DAY RANGE
$1.70 - $1.78
52 WEEK RANGE
$0.62 - $5.62
52 WEEK CHANGE
-$11.11
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Kevin S. Boyle
Region: US
Website: alaunos.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: alaunos.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.
Recent news